From April 24 to 25, 2024, a group of four people, including Zeng Bin, the vice president and secretary general of Chengdu High-tech Medical Association, and Ai He, the vice president and deputy secretary general, visited Shenzhen Translational Medicine Research Institute and Yin Hai Guang Quan Group in Shenzhen and Guangzhou for study.
On the afternoon of April 24, accompanied by Chen Shi, the president of Shenzhen Translational Medicine Research Institute, and Liu Yuchen, the vice president, they visited the experimental base of the research institute and had an in-depth communication and negotiation in the conference room. During the symposium, Vice President Liu Yuchen of the research institute warmly welcomed the arrival of the delegation from Chengdu High-tech Medical Association and gave a detailed introduction to the development history, basic research and innovative model of the research institute. The research institute integrates, optimizes scientific and technological resources, integrates and develops advantageous resources, and cooperates with enterprises. It focuses on original scientific theories and technological innovations from 0 to 1, mainly providing a high-end technical service platform for basic medical research and translational medical research and development. Secretary General Zeng Bin briefly introduced the situation and development of Chengdu High-tech Zone and Chengdu High-tech Medical Association and expressed deep respect for the scientists of the research institute who actively and passionately devote themselves to scientific research. Both sides expect that Chengdu High-tech Medical Association and the Translational Medicine Research Institute can have further in-depth cooperation in scientific research, jointly promote the process of transforming basic research into clinical application in their respective regions, and contribute to the field of medical science in their respective regions. On April 25, accompanied by Ning Jiaotao, the executive vice general manager of Yin Hai Guang Quan Group, they visited Guangzhou Zhiyi Biotechnology Co., Ltd. in Guangzhou Science City. The company is committed to the research and development of live biopharmaceuticals, mainly focusing on the field of digestion. Its first new drug pipeline has initiated Phase III clinical trials and has completed the first round of Series C financing. Subsequently, the delegation visited the Eye Health Science Popularization Hall of Guangzhou Yin Hai Eye and Visual Health Innovation Research Institute and Guangzhou Huangpu Yin Hai Eye Hospital of Yin Hai Guang Quan Group. They focused on understanding the medical environment, equipment configuration, the studio of the national master of traditional Chinese medicine and the series of products for myopia prevention and control and other industrialized products of Yin Hai System. During the symposium, Duan Junguo, the chairman of Yin Hai Guang Quan Group and the general president of Yin Hai Eye Hospitals, introduced that Yin Hai Guang Quan Group, as an advocate and leader of the full life cycle eye health management solution, is committed to building an ecological chain of the full industry of eye health; and focused on introducing the remarkable achievements of Yin Hai Eye Hospitals in the prevention and control of myopia among children and adolescents. Secretary General Zeng Bin said that Yin Hai Guang Quan Group has advanced practical experience in the "school doctor" cooperation for the prevention and control of myopia among adolescents. He hoped to have in-depth cooperation with Yin Hai Guang Quan Group in academic exchanges, discipline and organization construction, health science popularization and other aspects in Chinese and Western medicine ophthalmology. Finally, both sides look forward to continuously shaping and developing new advantages through focusing on academic and transformation cooperation and forming resource sharing, and injecting new-quality productive forces into the field of eye health.
